Association Between Malignancy and Topical Use of Pimecrolimus-Reference-Cited by-同舟云学术

Association Between Malignancy and Topical Use of Pimecrolimus

Published:2015-06-01 Issue:6 Volume:151 Page:594
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Margolis David J.¹,Abuabara Katrina²,Hoffstad Ole J.³,Wan Joy²,Raimondo Denise⁴,Bilker Warren B.³

Affiliation:

1. Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia2Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia

2. Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia

3. Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia

4. Valeant Pharmaceuticals International, Bridgewater, New Jersey

Publisher

American Medical Association (AMA)

Subject

Dermatology

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Italian S3-Guideline on the treatment of Atopic Eczema - Part 2: non-systemic treatments and treatment recommendations for special AE patient populations, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Occupational Dermatology (SIDAPA);Italian Journal of Dermatology and Venereology;2024-05

2. The role of disease registers in dermatology;British Journal of Dermatology;2024-01-04

3. Atopic Dermatitis: Disease Background and Risk Factors;Advances in Experimental Medicine and Biology;2024

4. Association Between the Use of Topical Calcineurin Inhibitors and the Risk of Cancer Among Patients with Atopic Dermatitis: A Nationwide, Population-Based, Retrospective Cohort Study;American Journal of Clinical Dermatology;2023-06-06

5. Safety of topical medications in the management of paediatric atopic dermatitis: An updated systematic review;British Journal of Clinical Pharmacology;2023-05-09